387 related articles for article (PubMed ID: 29571871)
21. Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report.
Shibata C; Kato J; Toda N; Imai M; Fukumura Y; Arai J; Kurokawa K; Kondo M; Takagi K; Kojima K; Ohki T; Seki M; Yoshida M; Suzuki A; Tagawa K
J Med Case Rep; 2019 Jun; 13(1):168. PubMed ID: 31153385
[TBL] [Abstract][Full Text] [Related]
22. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
Koda R; Watanabe H; Tsuchida M; Iino N; Suzuki K; Hasegawa G; Imai N; Narita I
BMC Nephrol; 2018 Feb; 19(1):48. PubMed ID: 29486725
[TBL] [Abstract][Full Text] [Related]
23. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma.
Tokumo K; Masuda T; Miyama T; Miura S; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Yoshida T; Iwamoto H; Fujitaka K; Hamada H; Hattori N
Lung Cancer; 2018 May; 119():21-24. PubMed ID: 29656748
[TBL] [Abstract][Full Text] [Related]
24. Continued Response to One Dose of Nivolumab Complicated by Myasthenic Crisis and Myositis.
Tan RYC; Toh CK; Takano A
J Thorac Oncol; 2017 Jul; 12(7):e90-e91. PubMed ID: 28629544
[No Abstract] [Full Text] [Related]
25. Severe infusion reaction due to nivolumab: A case report.
Kumari S; Yun J; Soares JR; Ding PN
Cancer Rep (Hoboken); 2020 Jun; 3(3):e1246. PubMed ID: 32671983
[TBL] [Abstract][Full Text] [Related]
26. Widespread Nivolumab-induced Enteropathy in a Long Responder Non-Small-cell Lung Cancer Patient.
Facchinetti F; Gnetti L; Caruana P; Fornaroli F; Luigi de'Angelis G; Sabato M; Ferri L; Cosenza A; Bordi P; Tiseo M
Clin Lung Cancer; 2018 Sep; 19(5):e591-e596. PubMed ID: 29801705
[No Abstract] [Full Text] [Related]
27. High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review.
Koyama N; Iwase O; Nakashima E; Kishida K; Kondo T; Watanabe Y; Takahashi H; Umebayashi Y; Ogawa Y; Miura H
BMC Pulm Med; 2018 Jan; 18(1):23. PubMed ID: 29378571
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy- A double Edged Sword; A case of Fatal Myocarditis and Complete Response.
Peters N; Greally M; Breen K; Fabre A; Blazkova S
Ir Med J; 2019 May; 112(5):937. PubMed ID: 31411390
[No Abstract] [Full Text] [Related]
29. Acute coronary syndrome and recurrent colitis as immune-related adverse events in a lung cancer patient.
Cancela-Díez B; Gómez-De Rueda F; Antolinos Pérez MJ; Jiménez-Morales A; López-Hidalgo JL
J Oncol Pharm Pract; 2020 Jan; 26(1):252-255. PubMed ID: 31382863
[TBL] [Abstract][Full Text] [Related]
30. Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma.
Mishima Y; Fukaishi T; Inase N; Isogai S
Intern Med; 2019 Mar; 58(5):693-697. PubMed ID: 30449786
[TBL] [Abstract][Full Text] [Related]
31. Myositis as a neuromuscular complication of immune checkpoint inhibitors.
Vermeulen L; Depuydt CE; Weckx P; Bechter O; Van Damme P; Thal DR; Claeys KG
Acta Neurol Belg; 2020 Apr; 120(2):355-364. PubMed ID: 31993961
[TBL] [Abstract][Full Text] [Related]
32. Pericardial effusion under nivolumab: case-reports and review of the literature.
Saade A; Mansuet-Lupo A; Arrondeau J; Thibault C; Mirabel M; Goldwasser F; Oudard S; Weiss L
J Immunother Cancer; 2019 Oct; 7(1):266. PubMed ID: 31627742
[TBL] [Abstract][Full Text] [Related]
33. Recurrent Episodes of Nivolumab-Induced Pneumonitis after Nivolumab Discontinuation and the Time Course of Carcinoembryonic Antigen Levels: A Case of a 58-Year-Old Woman with Non-Small Cell Lung Cancer.
de Jong C; Peters BJM; Schramel FMNH
Chemotherapy; 2018; 63(5):272-277. PubMed ID: 30572331
[TBL] [Abstract][Full Text] [Related]
34. Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report.
Ikeuchi K; Okuma Y; Tabata T
Lung Cancer; 2016 Sep; 99():148-50. PubMed ID: 27565931
[TBL] [Abstract][Full Text] [Related]
35. New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma.
Behling J; Kaes J; Münzel T; Grabbe S; Loquai C
Melanoma Res; 2017 Apr; 27(2):155-158. PubMed ID: 27977496
[TBL] [Abstract][Full Text] [Related]
36. Nivolumab-induced Pancreatitis: An Immune-related Adverse Event.
Saito H; Ono K
Radiology; 2019 Dec; 293(3):521. PubMed ID: 31617817
[No Abstract] [Full Text] [Related]
37. The Analysis of Renal Infiltrating Cells in Acute Tubulointerstitial Nephritis Induced by Anti-PD-1 Antibodies: A Case Report and Review of the Literature.
Tabei A; Watanabe M; Ikeuchi H; Nakasatomi M; Sakairi T; Kaneko Y; Maeshima A; Kaira K; Hirato J; Nojima Y; Hiromura K
Intern Med; 2018 Nov; 57(21):3135-3139. PubMed ID: 29877267
[TBL] [Abstract][Full Text] [Related]
38. Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient.
Karakas Y; Yuce D; Kılıckap S
Oncol Res Treat; 2017; 40(10):621-622. PubMed ID: 28950270
[No Abstract] [Full Text] [Related]
39. Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma.
Mazzaschi G; Bordi P; Fioretzaki R; Gnetti L; Milanese G; Tommasi C; Bersanelli M; Roti G; Scoditti U; Leonardi F; Quaini F; Tiseo M
Clin Lung Cancer; 2020 Mar; 21(2):e65-e73. PubMed ID: 31837925
[No Abstract] [Full Text] [Related]
40. Case 30-2019: A 65-Year-Old Woman with Lung Cancer and Chest Pain.
Guiney TE; Lopes MS; Kalra MK; Mooradian MJ; Neilan TG; Stone JR
N Engl J Med; 2019 Sep; 381(13):1268-1277. PubMed ID: 31553841
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
